UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Preference for a prefilled syringe or an autoinjection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study.(ORIGINAL RESEARCH)(Clinical report)

Patient preference and adherence, 2018-01, Vol.12, p.1193

2018

Link zum Volltext

Verfügbarkeit prüfen

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study

Patient preference and adherence, 2018-01, Vol.12, p.1193-1202

2018

Link zum Volltext

Verfügbarkeit prüfen

COVID‐19 and digestive health: Implications for prevention, care and the use of COVID‐19 vaccines in vulnerable patients

United European gastroenterology journal, 2021-11, Vol.9 (9), p.1091-1095

2021

Link zum Volltext

Verfügbarkeit prüfen

Is Crohn’s Disease a Rightly Used Eponym?

Journal of Crohn's and colitis, 2020-07, Vol.14 (6), p.867-871

2020

Link zum Volltext

Verfügbarkeit prüfen

W1194 Impact of an Extensive Thiopurine Methyltransferase (TPMT) Genotyping in Inflammatory Bowel Disease Patients Who Experienced Myelosuppression During Antipurine Therapy

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-671-S-671

2010

Link zum Volltext

Verfügbarkeit prüfen

In Memoriam: Emeritus Prof. Dr. Paul Rutgeerts (1948–2020)

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (6), p.1543-1545

2022

Link zum Volltext

Verfügbarkeit prüfen

Mo1558: REAL-WORLD EFFECTIVENESS AND SAFETY OF RISANKIZUMAB FOR MODERATE-SEVERE MULTI-REFRACTORY CROHN’S DISEASE: RESULTS FROM A BELGIAN MULTI-CENTRIC COHORT

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-818-S-819

2022

Link zum Volltext

Verfügbarkeit prüfen

Endoscopic removal of an extraluminal, intrapancreatic dislocated common bile duct stone

Endoscopy, 2020-02, Vol.52 (2), p.E59

2020

Link zum Volltext

Verfügbarkeit prüfen

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Inflammatory bowel diseases, 2019-01, Vol.25 (1), p.156-162

2019

Link zum Volltext

Verfügbarkeit prüfen

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

The lancet. Gastroenterology & hepatology, 2023-03, Vol.8 (3), p.215-227

2023

Link zum Volltext

Verfügbarkeit prüfen

Jejuno-ileal diverticulosis : a review of literature

Acta gastro-enterologica belgica, 2018-10, Vol.81 (4), p.517-519

2018

Link zum Volltext

Verfügbarkeit prüfen

Mo1847 - Reactive Dose Escalation of Infliximab in Patients with Crohn's Disease in Tailorix Leads to Improved Outcomes

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-823-S-824

2018

Link zum Volltext

Verfügbarkeit prüfen

946 DEEP REMISSION AT 1 YEAR IS NOT ASSOCIATED WITH BETTER OUTCOME IN CROHN'S DISEASE: LONG-TERM DATA FROM TAILORIX

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-192-S-192

2020

Link zum Volltext

Verfügbarkeit prüfen

Tu1895 TOFACITINIB INDUCES CLINICAL AND ENDOSCOPIC REMISSION IN BIOLOGIC REFRACTORY ULCERATIVE COLITIS PATIENTS: A REAL-WORLD BELGIUM COHORT STUDY

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1208-S-1208

2020

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 and digestive health

United European gastroenterology journal, 2020-06, Vol.8 (5), p.624-626

2020

Link zum Volltext

Verfügbarkeit prüfen

Mo1910 – Long-Term Clinical Efficacy of Ustekinumab in Refractory Crohn’s Disease: A Multi-Centre Belgian Cohort Study

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-882-S-883

2019

Link zum Volltext

Verfügbarkeit prüfen

Mo1865 - Ustekinumab Induces Clinical and Biological Remission in Biologic Refractory Crohn's Disease Patients: A Real World Belgian Cohort Study

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-830-S-831

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response

GastroHep, 2021-03, Vol.3 (2), p.63-71

2021

Link zum Volltext

Verfügbarkeit prüfen

692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX)

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S143-S143

2016

Link zum Volltext

Verfügbarkeit prüfen

Liver disease late in pregnancy without pre-eclampsia

Acta gastro-enterologica belgica, 2017-01, Vol.80 (1), p.53-57

2017

Link zum Volltext

Verfügbarkeit prüfen

Serum bilirubins in hepatobiliary disease: Comparison with other liver function tests and changes in the postobstructive period

Hepatology (Baltimore, Md.), 1985-01, Vol.5 (1), p.112-117

1985

Link zum Volltext

Verfügbarkeit prüfen

Outcomes after Surgical Treatment of Oesophagogastric Cancer with Synchronous Liver Metastases: A Multicentre Retrospective Cohort Study

Cancers, 2024-02, Vol.16 (4), p.797

2024

Link zum Volltext

Verfügbarkeit prüfen

An International Multicenter Study Exploring Whether Surveillance After Esophageal Cancer Surgery Impacts Oncological and Quality of Life Outcomes (ENSURE)

Annals of surgery, 2023-05, Vol.277 (5), p.e1035

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

ThemaRemission Induction

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Gastroenterology & Hepatology
(14)
Humans
(11)
Female
(6)
Gastroentérologie & Hépatologie
(5)
Human Health Sciences
(5)
Male
(5)
Sciences De La Santé Humaine
(5)
Adult
(4)
Medical Research
(4)
Surgery
(4)
Treatment Outcome
(4)
Tumors
(4)
Ulcerative Colitis
(4)
Anti-Tnf
(3)
Antibodies, Monoclonal - Therapeutic Use
(3)
Care And Treatment
(3)
Colitis
(3)
Golimumab
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

Preference for a prefilled syringe or an autoinjection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study.(ORIGINAL RESEARCH)(Clinical report)

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study

COVID‐19 and digestive health: Implications for prevention, care and the use of COVID‐19 vaccines in vulnerable patients

Is Crohn’s Disease a Rightly Used Eponym?

W1194 Impact of an Extensive Thiopurine Methyltransferase (TPMT) Genotyping in Inflammatory Bowel Disease Patients Who Experienced Myelosuppression During Antipurine Therapy

In Memoriam: Emeritus Prof. Dr. Paul Rutgeerts (1948–2020)

Mo1558: REAL-WORLD EFFECTIVENESS AND SAFETY OF RISANKIZUMAB FOR MODERATE-SEVERE MULTI-REFRACTORY CROHN’S DISEASE: RESULTS FROM A BELGIAN MULTI-CENTRIC COHORT

Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease

Endoscopic removal of an extraluminal, intrapancreatic dislocated common bile duct stone

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Jejuno-ileal diverticulosis : a review of literature

Mo1847 - Reactive Dose Escalation of Infliximab in Patients with Crohn's Disease in Tailorix Leads to Improved Outcomes

946 DEEP REMISSION AT 1 YEAR IS NOT ASSOCIATED WITH BETTER OUTCOME IN CROHN'S DISEASE: LONG-TERM DATA FROM TAILORIX

Tu1895 TOFACITINIB INDUCES CLINICAL AND ENDOSCOPIC REMISSION IN BIOLOGIC REFRACTORY ULCERATIVE COLITIS PATIENTS: A REAL-WORLD BELGIUM COHORT STUDY

COVID-19 and digestive health

Mo1910 – Long-Term Clinical Efficacy of Ustekinumab in Refractory Crohn’s Disease: A Multi-Centre Belgian Cohort Study

Mo1865 - Ustekinumab Induces Clinical and Biological Remission in Biologic Refractory Crohn's Disease Patients: A Real World Belgian Cohort Study

Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response

692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX)

Liver disease late in pregnancy without pre-eclampsia

Serum bilirubins in hepatobiliary disease: Comparison with other liver function tests and changes in the postobstructive period

Outcomes after Surgical Treatment of Oesophagogastric Cancer with Synchronous Liver Metastases: A Multicentre Retrospective Cohort Study

An International Multicenter Study Exploring Whether Surveillance After Esophageal Cancer Surgery Impacts Oncological and Quality of Life Outcomes (ENSURE)

Aktive Filter

Suchergebnisse filtern